MX2014004679A - Preparacion de liberacion sostenida. - Google Patents
Preparacion de liberacion sostenida.Info
- Publication number
- MX2014004679A MX2014004679A MX2014004679A MX2014004679A MX2014004679A MX 2014004679 A MX2014004679 A MX 2014004679A MX 2014004679 A MX2014004679 A MX 2014004679A MX 2014004679 A MX2014004679 A MX 2014004679A MX 2014004679 A MX2014004679 A MX 2014004679A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained
- release preparation
- pioglitazone
- salt
- average
- Prior art date
Links
- 239000003405 delayed action preparation Substances 0.000 title abstract 3
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 6
- 229960005095 pioglitazone Drugs 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000007922 dissolution test Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000012085 test solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011232302 | 2011-10-21 | ||
| PCT/JP2012/077662 WO2013058409A1 (en) | 2011-10-21 | 2012-10-19 | Sustained-release preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014004679A true MX2014004679A (es) | 2014-08-01 |
Family
ID=47178262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014004679A MX2014004679A (es) | 2011-10-21 | 2012-10-19 | Preparacion de liberacion sostenida. |
Country Status (30)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014008744A2 (pt) | 2011-10-21 | 2017-04-18 | Takeda Pharmaceuticals Co | preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer |
| SG11201401189WA (en) | 2012-04-20 | 2014-09-26 | Gilead Sciences Inc | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection |
| US20150141517A1 (en) * | 2013-11-15 | 2015-05-21 | Shin-Etsu Chemical Co., Ltd. | Granulated composite, rapid release tablet and method for producing same |
| KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
| UY39094A (es) * | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
| JP2023066053A (ja) * | 2021-10-28 | 2023-05-15 | 東和薬品株式会社 | 放出制御医薬組成物 |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810502A (en) | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
| JPH0624959A (ja) | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
| DK0661045T3 (da) | 1992-09-18 | 2002-10-28 | Yamanouchi Pharma Co Ltd | Hydrogelpræparat med forsinket frigivelse |
| JPH06316517A (ja) | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| AU8532798A (en) | 1997-06-13 | 1998-12-30 | Roland Bodmeier | Compounds which delay the release of active substances |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| WO2003013609A1 (fr) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Medicaments a liberation continue |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| EP2604266A1 (en) | 2002-09-20 | 2013-06-19 | Andrx Labs Llc | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| IN192749B (cg-RX-API-DMAC7.html) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| EP1607088B1 (en) | 2003-03-17 | 2019-02-27 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| JP4933033B2 (ja) | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| JP2005015477A (ja) | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
| CA2528164A1 (en) | 2003-06-06 | 2004-12-16 | Takeda Pharmaceutical Company Limited | Solid preparation |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| WO2005099760A1 (ja) | 2004-04-14 | 2005-10-27 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| MX2007002375A (es) | 2004-08-31 | 2007-04-23 | Pfizer Prod Inc | Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad. |
| TW200803851A (en) | 2005-09-22 | 2008-01-16 | Sb Pharmco Inc | Pharmaceutical composition for improvement of cognitive function |
| WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
| AU2006328328B2 (en) | 2005-12-22 | 2012-08-30 | Takeda Pharmaceutical Company Limited | Solid preparation containing an insulin sensitizer |
| AU2007232836B2 (en) | 2006-03-30 | 2012-12-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Solid pharmaceutical preparation |
| JP2009534292A (ja) | 2006-04-27 | 2009-09-24 | 武田薬品工業株式会社 | 塩酸ピオグリタゾンを有するアンジオテンシンｉｉ拮抗薬の医薬組成物 |
| DK2120878T3 (da) | 2007-02-09 | 2014-11-03 | Alphapharm Pty Ltd | Doseringsform indeholdende to aktive farmaceutiske ingredienser i forskellige fysiske former |
| TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| CN101269040A (zh) | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 盐酸吡格列酮缓释滴丸及其制备方法 |
| US8445190B2 (en) | 2008-09-30 | 2013-05-21 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| WO2011049309A2 (ko) | 2009-10-09 | 2011-04-28 | 영진약품공업 주식회사 | 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| JP2011232302A (ja) | 2010-04-30 | 2011-11-17 | Ricoh Elemex Corp | 画像検査方法及び画像検査装置 |
| CN101884627B (zh) * | 2010-07-07 | 2012-01-25 | 青岛黄海制药有限责任公司 | 盐酸吡格列酮胃内滞留缓释片及其制备方法 |
| KR102171747B1 (ko) * | 2011-01-10 | 2020-11-04 | 진판델 파마슈티컬스 인코포레이티드 | 알츠하이머 병 치료를 위한 방법 및 약품 |
| BR112014008744A2 (pt) | 2011-10-21 | 2017-04-18 | Takeda Pharmaceuticals Co | preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer |
| KR20160056691A (ko) | 2014-11-12 | 2016-05-20 | 삼성에스디아이 주식회사 | 이차전지 |
-
2012
- 2012-10-19 BR BR112014008744A patent/BR112014008744A2/pt not_active IP Right Cessation
- 2012-10-19 MX MX2014004679A patent/MX2014004679A/es unknown
- 2012-10-19 WO PCT/JP2012/077662 patent/WO2013058409A1/en not_active Ceased
- 2012-10-19 SG SG2014012025A patent/SG2014012025A/en unknown
- 2012-10-19 PH PH1/2014/500856A patent/PH12014500856A1/en unknown
- 2012-10-19 IN IN3169DEN2014 patent/IN2014DN03169A/en unknown
- 2012-10-19 EA EA201490840A patent/EA201490840A1/ru unknown
- 2012-10-19 SG SG10201700121YA patent/SG10201700121YA/en unknown
- 2012-10-19 PE PE2014000558A patent/PE20141189A1/es not_active Application Discontinuation
- 2012-10-19 KR KR1020147010504A patent/KR20140081826A/ko not_active Ceased
- 2012-10-19 EP EP12784752.3A patent/EP2768487B1/en active Active
- 2012-10-19 CN CN201280062591.4A patent/CN104039313A/zh active Pending
- 2012-10-19 AP AP2014007645A patent/AP2014007645A0/xx unknown
- 2012-10-19 UA UAA201405332A patent/UA113858C2/uk unknown
- 2012-10-19 AU AU2012326976A patent/AU2012326976B2/en not_active Ceased
- 2012-10-19 CA CA2852417A patent/CA2852417A1/en not_active Abandoned
- 2012-10-19 UY UY0001034403A patent/UY34403A/es not_active Application Discontinuation
- 2012-10-19 US US14/352,785 patent/US9907789B2/en active Active
- 2012-10-19 TW TW101138592A patent/TW201323018A/zh unknown
- 2012-10-19 AR ARP120103908A patent/AR088398A1/es unknown
- 2012-10-19 JP JP2014518853A patent/JP6093762B2/ja not_active Expired - Fee Related
- 2012-10-19 NZ NZ624275A patent/NZ624275A/en not_active IP Right Cessation
-
2014
- 2014-04-11 TN TNP2014000152A patent/TN2014000152A1/en unknown
- 2014-04-13 IL IL232114A patent/IL232114A0/en unknown
- 2014-04-15 DO DO2014000077A patent/DOP2014000077A/es unknown
- 2014-04-17 CL CL2014000992A patent/CL2014000992A1/es unknown
- 2014-04-29 EC ECSP14013328 patent/ECSP14013328A/es unknown
- 2014-04-29 ZA ZA2014/03103A patent/ZA201403103B/en unknown
- 2014-05-09 CR CR20140213A patent/CR20140213A/es unknown
- 2014-05-14 CO CO14103846A patent/CO6960544A2/es unknown
- 2014-05-15 MA MA37034A patent/MA35717B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000152A1 (en) | Sustained-release preparation | |
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| NZ602685A (en) | Concentrated protein formulations and uses thereof | |
| EP2883932A3 (en) | Aqueous solution and method for use thereof | |
| MX2017007178A (es) | Formulaciones liquidas estables de virus de vacuna. | |
| PH12013500223A1 (en) | Oral care product and methods of use and manufacture thereof | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| PH12016501175B1 (en) | Formulations of deoxycholic acid and salts thereof | |
| ZA202210899B (en) | Solutons for increasing the stability and shelf life of an organ and tissue preservation solution | |
| EA201690079A1 (ru) | Композиция, содержащая глутаминовую-n,n-диуксусную кислоту (glda), воду и фермент | |
| ZA201504284B (en) | Solution for preserving vascular conduits | |
| PH12017501397A1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| AU2018258588A8 (en) | Inhibitors of TRIM33 and methods of use | |
| PH12014502407A1 (en) | New alfentanil composition for the treatment of acute pain | |
| WO2012074237A3 (ko) | 도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물 | |
| EA201390844A1 (ru) | Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения | |
| MY163015A (en) | Dentifrice composition | |
| UA110933C2 (uk) | Композиція для лікування есенціальної тромбоцитемії | |
| TN2010000012A1 (en) | Stable pharmaceutical composition of a water soluble vinorelbine salt | |
| TR201009399A2 (tr) | Hızlı çözünen efervesan rosuvastatin formülasyonları. | |
| WO2009155488A3 (en) | Novel oxalate salt and crystal of o-desmethylvenlafaxine | |
| MX2009009830A (es) | Composiciones farmaceuticas estables y metodos de fabricacion y uso de las mismas. | |
| MX2023013066A (es) | Formulaciones de etelcalcetida. | |
| TH156810A (th) | สารเตรียมชนิดปลดปล่อยแบบทยอย | |
| WO2012036529A3 (en) | (s)-n,n-dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine derivatives, pharmaceutical compositions containing the derivatives and manufacturing methods thereof |